02325 雲康集團
YUNKANG GROUP
YUNKANG GROUP
| Listing Date | 2022/05/18 |
| Listing Price | 7.890 |
Subscription Result
- Subscription Rate1.35x
- Guarantee One Lot Size1 lot
- One Lot Success Rate100%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Yunkang Group is a medical operation service provider in China offering a full suite of diagnostic testing services for medical institutions with a market share of 3.7% in China’s medical operation service market in terms of revenue in 2020.
Medical operation services primarily relate to diagnostic testing services provided to medical institutions which can be divided into diagnostic outsourcing services and diagnostic testing services for medical institution alliances. It provides such diagnostic testing services to medical institutions in its six independent clinical laboratories and on-site diagnostic centers in medical institutions. It also provides diagnostic testing services to non-medical institutions in China via an outpatient clinic.
Up to April 2022, the Group had assisted in establishing and operating 322 on-site diagnostic centers, serving over 700 medical institutions under its diagnostic testing services for medical institution alliances. Its customers primarily consisted of hospitals, community health clinics and non-medical institutions.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 138.19M shares |
| No. of International Offer Shares | 124.37M shares |
| No. of HK Offer Shares | 13.82M shares |
| Offer Price | $7.89 |
| Stock Code | 2325 |
| Sponsor(s) | CMB International Capital Limited, SPDB International Capital Limited |
| Underwriter(s) | CMB International Capital Limited, SPDB International Capital Limited, China Merchants Securities (HK) Co., Limited, CCB International Capital Limited, CRIC Securities Company Limited, Futu Securities International (Hong Kong) Limited, Blackwell Global Securities Limited, Livermore Holdings Limited |
TIME TABLE
| Application Period | May 05 (Thu) - noon, May 11 (Wed) |
| Price Determination Date | May 11 (Wed) |
| Result Announcement Date | On or before May 17 (Tue) |
| Result Announcement Date | On or before May 17 (Tue) |
| Dealings in Shares commence on | May 18, 2022. (Wed) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $7.89 |
| Capitalization | 4.84B |
| NAV / share ($) | $4.18 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 7.89, the net proceeds raised would be HKD 760.90M, of which |
| 55% : expanding and deepening medical institution alliance network over the next five years |
| 20% : upgrading and enhancing operational capabilities and digitalize testing services |
| 10% : expanding diagnostic capabilities with a focus on developing capabilities in key technologies |
| 5% : potential investment and acquisition opportunities |
| 5% : recruiting and training up talent pool |
| 5% : working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).